NASDAQ:TCRR

TCR2 Therapeutics (TCRR) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.48
▼
$1.63
50-Day Range: $1.48
▼
$1.98
52-Week Range: $0.82
▼
$3.88

Volume: 3.91 million shs
Average Volume: 494,777 shs
Market Capitalization: $58.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.91

TCR2 Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.14 Rating Score
Upside/Downside: 232.0% Upside
$4.91 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.65
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.68) to ($0.79) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

184th out of 969 stocks

Biological Products, Except Diagnostic Industry

23rd out of 161 stocks

3.1

Analyst's Opinion

Consensus Rating
TCR2 Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.91, TCR2 Therapeutics has a forecasted upside of 232.0% from its current price of $1.48.
Amount of Analyst Coverage
TCR2 Therapeutics has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for TCRR.

0.0

Dividend Strength

Dividend Yield
TCR2 Therapeutics does not currently pay a dividend.
Dividend Growth
TCR2 Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
TCR2 Therapeutics has received a 75.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for TCR2 Therapeutics is -0.65.

N/A

News and Social Media Coverage

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TCR2 Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
25.01% of the stock of TCR2 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
64.76% of the stock of TCR2 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for TCR2 Therapeutics are expected to grow in the coming year, from ($2.68) to ($0.79) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TCR2 Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TCR2 Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TCR2 Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About TCR2 Therapeutics (NASDAQ:TCRR) Stock

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

June 20, 2023 | wsj.com

DICE Therapeutics Inc.

June 1, 2023 | finance.yahoo.com

Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!

May 16, 2023 | benzinga.com

TCR2 Therapeutics Insider Trades Send a Signal

May 12, 2023 | msn.com

Recap: TCR2 Therapeutics Q1 Earnings

May 11, 2023 | marketwatch.com

10-Q: TCR2 THERAPEUTICS INC.

May 11, 2023 | finance.yahoo.com

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

April 15, 2023 | finance.yahoo.com

Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Risky

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

March 25, 2023 | msn.com

Mizuho Downgrades Tcr2 Therapeutics (TCRR)

March 23, 2023 | markets.businessinsider.com

TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho Securities

March 23, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)

March 23, 2023 | finanznachrichten.de

TCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 23, 2023 | finance.yahoo.com

TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 9, 2023 | msn.com

What To Know About Jefferies's Downgrade of TCR2 Therapeutics

March 9, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About TCR2 Therapeutics

March 8, 2023 | markets.businessinsider.com

TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. Wainwright

March 6, 2023 | benzinga.com

Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmune

March 6, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. Buyout

March 6, 2023 | investorplace.com

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

March 6, 2023 | finanznachrichten.de

TCR2 Therapeutics: Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

March 6, 2023 | markets.businessinsider.com

Adaptimmune To Combine With TCR² In All-stock Deal - Quick Facts

March 6, 2023 | finance.yahoo.com

Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

March 6, 2023 | finance.yahoo.com

Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

February 16, 2023 | benzinga.com

TCR2 Therapeutics Stock (NASDAQ:TCRR), Quotes and News Summary

February 8, 2023 | finance.yahoo.com

TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023

January 18, 2023 | reuters.com

TCRR.C - | Stock Price & Latest News | Reuters

See More Headlines

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Company Calendar

Last Earnings: 11/10/2021
Today: 9/28/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TCRR
CUSIP: N/A
CIK: 1750019
Web: www.tcr2.com
Phone: (617) 949-5200
Fax: N/A
Employees: 137
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.91
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $1.68
Forecasted Upside/Downside: +232.0%
Consensus Rating: Hold
Rating Score (0-4): 2.14
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-151,820,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -97.81%
Return on Assets: -69.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.96
Quick Ratio: 2.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.58 per share
Price / Book: 0.57

Miscellaneous

Outstanding Shares: 39,260,000
Free Float: 29,443,000
Market Cap: $58.10 million
Optionable: Not Optionable
Beta: 1.95

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Garry E. Menzel
President, Chief Executive Officer & Director

Peter Olagunju
Chief Operating Officer

Eric M. Sullivan
Chief Financial Officer

Alfonso Quintás-Cardama
Chief Medical Officer

Praveen Malhotra
Vice President-Information Technology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TCRR Stock - Frequently Asked Questions

Should I buy or sell TCR2 Therapeutics stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TCRR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRR, but not buy additional shares or sell existing shares.
View TCRR analyst ratings or view top-rated stocks.
What is TCR2 Therapeutics' stock price forecast for 2023?: 7 Wall Street analysts have issued twelve-month target prices for TCR2 Therapeutics' stock. Their TCRR share price forecasts range from $1.68 to $13.00. On average, they predict the company's stock price to reach $4.91 in the next year. This suggests a possible upside of 232.0% from the stock's current price.
View analysts price targets for TCRR or view top-rated stocks among Wall Street analysts.
How were TCR2 Therapeutics' earnings last quarter?: TCR2 Therapeutics Inc. (NASDAQ:TCRR) issued its earnings results on Wednesday, November, 10th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.06.
What other stocks do shareholders of TCR2 Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).
When did TCR2 Therapeutics IPO?: (TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?: TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."
Who are TCR2 Therapeutics' major shareholders?: TCR2 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%). Insiders that own company stock include Alfonso Quintas Cardama, Garry E Menzel, Kevin C Tang, Mayur Ian Somaiya, Mpm Asset Management Llc and Robert Hofmeister.
View institutional ownership trends.
What is TCR2 Therapeutics' stock price today?: One share of TCRR stock can currently be purchased for approximately $1.48.
How much money does TCR2 Therapeutics make?: TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $58.10 million. The company earns $-151,820,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis.
How many employees does TCR2 Therapeutics have?: The company employs 137 workers across the globe.
How can I contact TCR2 Therapeutics?: TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com.

This page (NASDAQ:TCRR) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

TCR2 Therapeutics (TCRR) Stock Forecast, Price & News

TCR2 Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Company Ownership

Earnings and Valuation

About TCR2 Therapeutics (NASDAQ:TCRR) Stock

TCRR Stock News Headlines

TCRR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TCRR Stock - Frequently Asked Questions

Overall MarketRank^™